Kornimate/medical-research-clean huggingface dataset:
optimal frequency of high-intensity interval training for centrally obese adults

Conditions: Obesity

Summary: the aim of this study is to examine the therapeutic effectiveness of two different exercise frequencies of high-intensity interval training (hiit; once versus thrice weekly, with matched weekly exercise volume) on improving cardiometabolic risk factors in centrally obese adults.

hiit is an emerging, popular, promising, cost-effective, and time-efficient exercise modality for managing obesity. although lower-frequency hiit is favorable for intervention adherence, the optimal exercise frequency of hiit for alleviating obesity is unknown. this study is a three-arm randomized controlled trial. centrally obese adults will be randomly allocated to three groups: the usual care control, once and thrice-weekly hiit groups. led by research personnel, the usual care group will receive obesity-related health education. led by athletic coaches, the hiit intervention groups will receive 16 weeks of once or thrice weekly hiit (with matched weekly exercise volume). outcome measures of this study will be examined at baseline, 4 months (post-intervention), and 8 months (follow-up), by assessors blinded to group allocation.

Eligibility criteria:
inclusion criteria: * aged above 18 years * ethnic chinese * overweight (bmi ≥23 for asian) * centrally obese according to idf and ncep with asian-specific cut-off (waist circumference ≥90 cm for males; ≥80 cm for females) * males and females exclusion criteria: * medical and somatic conditions that prevent brisk walking * chronic diseases affecting mobility and motor function (e.g., neurological disease, musculoskeletal disorder, spinal cord injury, autoimmune, arthritis, parkinson's disease) * chronic diseases affecting cardiorespiratory and metabolic health (e.g., cancers, cardio-/cerebrovascular diseases, heart disease, diabetes mellitus, pneumonia, chronic pulmonary diseases, nephritis, nephrosis) * signs of cardiac arrhythmia indicated by aberrant electrocardiography during incremental vo2max test * regular moderate-to-vigorous intensity exercise (≥150 min weekly) in the past 3 months, as screened by a specially designed questionnaire * daily smoking habit * excess alcohol consumption (daily ≥30g for men, ≥20g for women) in the past six months * claustrophobia * surgery, therapy or medication for obesity or weight loss in the past six months (e.g., gastric bypass, gastric band, sleeve gastrectomy, gastric reduction duodenal switch, and dietitian-prescribed dietary program)

Keywords: obesity central obesity high-intensity interval training aerobic exercise adults metabolic syndrome
web-based cognitive behavioral stress management for latino sexual minority men living with hiv and cancer

Conditions: HIV/AIDS; Cancer

Summary: this is a one year study to develop and test a culturally-tailored, web-based cognitive behavioral stress management (cbsm) intervention for latino sexual minority men living with both hiv and cancer. sexual minority latino men living with hiv and cancer experience a variety of health disparities related to their diagnoses, including higher distress. the project will use a single-group pre-post design. the project will use a community-based participatory research approach, and the investigators have included (and will continue to include) lgbt-serving community partners in all phases of the research from study design to implementation and dissemination of findings. the proposed study will aid in attenuating health disparities among latino sexual minority men living with hiv and cancer.


Eligibility criteria:
inclusion criteria: 1. have been diagnosed with at least one form of non-metastatic solid tumor cancer, 2. are ≥ 30 days post active primary treatment (i.e. surgery, radiation, and/or chemotherapy\*) for their cancer. (note: adjuvant therapies, such as hormone therapy for prostate cancer, etc. are not considered exclusionary), 3. self-identify as a sexual minority man, 4. have been diagnosed with hiv, 5. have reliable access to a computer/device with internet accessibility, and 6. are fluent english. exclusion criteria: 1. have had one of the following exclusionary cancer types: leukemia (or other cancers of the blood), non-melanoma skin cancer only (not in combination with another type listed in the inclusion criteria above), brain cancer, eye cancer, a form of pediatric cancer (if the pediatric cancer is the only cancer diagnosis the patient has had), 2. have a history of advanced (metastatic) cancer of any type or are currently undergoing primary treatment for their cancer, 3. have had inpatient treatment for severe mental illness in the past 12 months, or have overt signs of psychopathology (i.e. psychosis) and/or suicidality at the time of screening, 4. are experiencing active alcohol dependence, or have had inpatient treatment for alcohol abuse within the past 12 months, 5. are experiencing active substance dependence, or have had inpatient treatment for substance abuse within the past 12 months, and/or 6. have any other medical conditions resulting in a predicted life expectancy \<12 months.
traditional chinese medicine as preventive method for osteoporosis induced by adjuvant endocrine therapy

Conditions: Breast Cancer; Osteoporosis

Summary: to test the efficacy of two traditional chinese medicine in preventing osteoporosis in patients receiving adjuvant endocrine therapy.

breast cancer is the most common malignant tumor in female wolrdwide. results from clinical trials like atac trial have demonstrated the efficacy of ais in postmenopausal breast cancer patients. meanwhile it may cause a certain rate of osteoporosis in postmenopausal patients. the aim of this trial is to test the efficacy of two traditional chinese medicine in preventing osteoporosis in patients receiving adjuvant endocrine therapy.

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive breast cancer; * post-surgery, primary lesion been removed; * post-menopausal patients or pre-menopausal patients who will receive ovarian function suppression; * histologically confirmed er and/or pr positive ; * receiving adjuvant ais therapy in the following one years; * leukocyte ≥ 3\*10(9)/l; platelets ≥ 75\*10(9)/l; * serum glutamate oxaloacetate(ast/sgot) or serum glutamic-pyruvic transaminase(alt/sgpt) \<2.5 times of upper limit of normal range; * serum creatinine/blood urea nitrogen(bun) ≤ upper limit of normal (unl) range; * written informed consent according to the local ethics committee equirements; exclusion criteria: * metastatic breast cancer; * received neo-adjuvant endocrine therapy; * history of pelvic fracture or bone metabolic disease; * received drugs interfering bone metabolism in the last 12 months; * baseline bone mineral density: t \< -2sd; * with other primary malignant disease; * with severe non-malignant co-morbidity that will influence long-term follow up; * known severe hypersensitivity to any drugs in this study;

Keywords: chinese traditional medicine osteoporosis adjuvant endocrine therapy early breast cancer
proton cranio-spinal irradiation for leptomeningeal metastasis

Conditions: Leptomeningeal Metastasis

Summary: leptomeningeal metastasis is a rare but serious complication to cancer, with a grave prognosis. no efficient treatment exists. recent data suggest that craniospinal radiotherapy lead to superior survival and cns control compared to focal photon radiotherapy. we want to offer danish patients the new treatment, but within a protocol, as this is new data with an new treatment principle

patients must be referred from danish departments of oncology with radiotherapy service. patients with leptomeningeal metastasis from both solid and hematological cancers will be offered proton radiotherapy with 30 gy in 10 fractions to the entire craniospinal axis. patients will be followed with registration of side effects, neurology and mri scans every 3 months until 1 year.

Eligibility criteria:
inclusion criteria: * metastasis to the leptomeningeal space (lm) surrounding the brain and/ or spinal cord * metastasis verified by mri or csf cytology * karnofsky \>=60 (requiring some help, can take care of most personal requirements) * adequate bone marrow function * haemoglobin \> 5 mmol/l * absolute neutrophil count \>1 10\^9/l * platelet count \> 100 10\^9/l * patient consent * female subjects must either be of non-reproductive potential ( ≥ 60 years old, or with no menses for \>1 year without an alternative medical cause\], or history of hysterectomy, or history of bilateral tubal ligation, or history of bilateral oophorectomy) or must have a pregnancy test within 2 weeks prior to starting treatment. * patient at reproductive potential must agree to practice an effective contraceptive method. exclusion criteria: * • previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances (yang) * patient with multiple, serious major neurologic deficits per physician/investigator assessment including encephalopathy * patient with extensive systemic disease and without reasonable systemic treatment options * patient who is unable to undergo mri brain and spine with gadolinium contrast * pregnant or lactating women.
sklb1028, daunorubicin, and cytarabine in treating patients with newly diagnosed acute myeloid leukemia (aml)

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML)

Summary: the purpose of this study is to describe the dose limiting toxicities (dlt) of sklb1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. safety and tolerability of sklb1028 will also be evaluated. this study will also characterize the pharmacokinetics (pk) of sklb1028 when given in combination with cytarabine/daunorubicin remission induction and high-dose cytarabine (hidac) consolidation therapy in newly diagnosed acute myeloid leukemia .


Eligibility criteria:
inclusion criteria: 1. subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (aml) \> 20% blasts in the bone marrow according to who classification (2016) documented prior to enrollment.; 2. age ≥ 18 and \< 60 years; 3. subjects who are positive for flt3 mutations by central laboratory; 4. subject has an eastern cooperative oncology group (ecog) performance status ≤ 2; 5. subject must meet the following criteria as indicated on the clinical laboratory tests; 1. serum aspartate aminotransf 2. total serum bilirubin ≤ 2.5 x institutional uln 3. serum creatinine ≤ 3 x institutional uln or an estimated glomerular filtration rate (egfr) of \> 30 ml/min 6. subject is suitable for oral administration of study drug. exclusion criteria: 1. confirmed diagnosis of acute promyelocytic leukemia (m3 /apl), or bcr-abl positive leukemia (ie, blast crisis of chronic myelogenous leukemia); 2. diagnosis of active malignancy other than aml; 3. aml secondary to radiotherapy or chemotherapy for other tumors; 4. aml with central nervous system involvement; 5. refractory hypokalemia or hypomagnesemia that is not easily corrected by symptomatic treatment and that occurs repeatedly in the past; 6. current clinically significant graft-ve 7. previous history of other malignancies. 8. patients with clinically significant coagulation abnormalities, such as disseminated intravascular coagulation (dic), hemophilia a, hemophilia b, and von willebrand disease; 9. major surgery of major organs has been performed before entering the study (for the definition of major surgery, refer to grade 3 and 4 surgery specified in management measures for clinical application of medical technology, or the patient has not yet fully recovered from 10. subject has received prior therapy for aml with the following exceptions: a. emergency leukapheresis; b. emergency treatment with hydroxyurea ;c. growth factor or cytokine support; d. steroid for anaphylaxis or transfusion reaction;
data driven behavior intervention and medical outcome evaluation of patients' comprehensive monitoring

Conditions: Metabolic Syndrome; Metabolic Disturbance; Metabolic Complication; Infection; Obesity; Diabetes

Summary: during the study, the resuscitation room, general wards and icu were installed fixed or mobile acquisition devices in the resuscitation room, the emergency department of peking union medical college hospital, and the collection platform was set up. patients with acute diseases (infection, diabetes complications, etc.) caused by metabolic syndrome (obesity, diabetes, etc.) were selected after informed consent. all medical intervention behaviors, relevant medical records and medical outcome records within the collection scope of the device platform were collected prospectively . and regular follow-up, guidance of patients with metabolic syndrome control, while collecting all the lifestyle characteristics of patients, some patients with metabolic cabin research, and observe the relevant medical outcomes. after that, all the collected data were coded, and the influence of all lifestyle and medical behavior interventions on patients' medical outcomes was studied by artificial intelligence method.


Eligibility criteria:
inclusion criteria: * diabetes and / or obesity (bmi\>=28). * emergency room / emergency ward / eicu; * be able to understand and agree the research protocol and sign the informed consent exclusion criteria: * pregnant women / lactation period; * the estimated survival time was less than 1 year; * long term follow-up is not guaranteed; * failure to comply with the protocol or procedure; * the collection of medical behavior data can not complete the de privacy or label after de privacy; * other researchers think that it is not suitable for inclusion

Keywords: metabolic diabetes obesity infection complication
periarticular injection versus peripheral nerve block in total hip arthroplasty

Conditions: Hip Arthropathy

Summary: this study will assess if preoperative quadratus lumborum block (qlb)/lateral femoral cutaneous nerve block (lfcnb) with ropivacaine and glucocorticoids provide more effective analgesia than periarticular injection (pai) with the same mixture in total hip arthroplasty (tha).

to support our hypothesis that preoperative quadratus lumborum block (qlb)/lateral femoral cutaneous nerve block (lfcnb) provides more effective analgesia than periarticular injection (pai) in total hip arthroplasty (tha), we will look at the following outcomes: primary outcome: daily opioid consumption secondary outcomes: pain intensity and physical functioning while in the hospital: using pain inventory modified from brief pain inventory and length of hospital stays. since both qlb/lfcnb nerve block and pai techniques are both routinely used as standard of care anesthesia for tha, the study intervention will be the randomization to assign patients to one of these treatment options and assess their response from post-op patient questionnaires and data collection. when results were entered, the detailed description was updated to reflect the outcome measures used in the study.

Eligibility criteria:
inclusion criteria: * elective unilateral primary tha * all surgical approaches * american society of anesthesiologist (asa) status i, ii and iii. exclusion criteria: * patient refusal; * age less than 18 years * those with cognitive dysfunction, psychiatric disorder, or non-english speaking patients that cannot consent or communicate clear understanding of the protocol with research team; * coagulopathy;
long-term immunogenicity of a hpv vaccine in sle

Conditions: Systemic Lupus Erythematosus

Summary: to study the 5-year immunogenicity against a quadrivalent hpv vaccine in patients with sle and healthy controls.

most cases of human papilloma virus (hpv) infection are asymptomatic, transient and resolve without treatment. however, in some individuals, especially those patients who are immunocompromised because of various underlying diseases and those who are receiving long-term immunosuppressive agents, hpv infection is persistent and may result in genital warts, cervical smear abnormalities, cervical intraepithelial neoplasia (cin) and rarely cervical cancer. high-risk hpv serotypes are those which are oncogenic and associated with invasive cancers of the cervix and vulva. examples are the hpv 16 and hpv 18. hpv 16 accounts for almost half of all cervical cancers whereas hpv 18 infection is present in 10-12% of all cervical cancers. systemic lupus erythematosus (sle) patients are at risk of persistent hpv infection. this is because of the immune aberration related to the disease itself and the immunosuppressive state induced by various treatments. one study of 85 sle patients revealed a 16.5% prevalence of abnormal pap smears and 12% prevalence of cervical squamous intraepithelial neoplasia (cin) on routine screening, which was significantly higher than those figures reported in age-matched healthy women (corresponding figures for abnormal pap smear and cin were 5.7% and 2%, respectively). thus, prevention of hpv infection is important in patients with sle in order to reduce the incidence of cin lesions and hence invasive cervical cancers in the long run. the investigators have conducted a case-control study on the safety and immunogenicity of the quadrivalent hpv vaccine, gardasil, in 2010. fifty female sle patients and 50 age-matched healthy controls were studied. at month 12 after vaccination, the sero-conversion rates of anti-hpv serotypes 6, 11, 16 and 18 in patients and controls were 82%, 89%, 95%, 76% and 98%, 98%, 98%, 80%, respectively. injection site reaction was the commonest adverse event (ae) (5%), and the incidence of aes was comparable between patients with sle and controls. the investigators plan to study the long-term immunogenicity (durability of the immune response) of the hpv vaccine in the same cohort of patients and controls followed for 5 years. in particular, in patients with sle, the investigators would like to evaluate the effect of disease flares and ongoing immunosuppressive treatment on the immune response to the hpv serotypes 5 years after vaccination.

Eligibility criteria:
inclusion criteria: sle patients 1. female patients aged 18-35 years 2. fulfilling the american college of rheumatology (acr) criteria for the classification of sle 3. having participated in the investigators' original hpv study in 2010 4. able to give written informed consent controls 1. women aged 18-35 years, matched those of sle patients recruited 2. no known chronic medical diseases 3. having participated in our hpv study in 2010

Keywords: lupus
safety of pentoxifylline and vitamin e with stereotactic ablative radiotherapy (sabr) in non-small cell lung cancers

Conditions: Non-small Cell Lung Cancers

Summary: the objective of this prospective phase ii protocol is to assess the toxicity and efficacy of pentoxifylline and sabr in the re-treatment of recurrent or new lung cancers


Eligibility criteria:
3.1 inclusion criteria: - eligibility criteria 3.1.1 age \>/= 18 years 3.1.2 ecog performance status 0-1 3.1.3 histologically proven diagnosis of a prior thoracic malignancy treated with thoracic external beam radiotherapy with or without systemic chemotherapy 3.1.4 pathologic or clinical diagnosis of a new or loco-regional recurrent lung malignancy. a reasonable attempt should be made to make a pathologic diagnosis of malignancy (ie. bronchoscopy, ct guided lung biopsy) * loco-regional is defined as recurrence within the region of the primary tumor or adjacent draining lymph node regions. * the new lesion or loco-regional recurrence must be within or adjacent to the previously irradiated treatment volume. 3.1.5 imaging as follows: * ct scan of the chest with iv contrast within 8 weeks of registration * whole body pet scan within 8 weeks of registration 3.1.6 pulmonary function test (pfts), including diffusion capacity within 8 weeks of registration 3.1.7 negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential. 3.1.6 women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control 3.1.7 patients must provide study specific informed consent prior to study entry. exclusion criteria: - 3.2 exclusion criteria 3.2.1. no previously reported thoracic radiotherapy 3.2.2. fev1 \<20% predicted and/or dlco \<20% predicted 3.2.2. pregnant women or lactating women 3.2.3 chemotherapy within 4 weeks of the initiation of sabr 3.2.4 plans to administer systemic chemotherapy overlapping with radiotherapy
efficacy of egf-loaded self healing gel in treatment of oral mucositis

Conditions: Oral Mucositis

Summary: cancer treatment, including radiation along with aggressive chemotherapy, increases the patient's survival rate. however, they possess toxic side effects. oral mucositis is one of the most serious complications of cancer treatment, which occurs in most of patients receiving cancer therapy. mucositis can dramatically affect the patient's quality of life .epidermal growth factor (egf) is a dominant factor in early keratinocyte differentiation, proliferation and migration. however, a major obstacle in most studies is that there isn't prolonged contact between the applied treatment and the oral mucosa to achieve the optimum therapeutic effect. thus, a new vehicle for egf is needed to achieve sufficient prolonged contact with oral mucosa. the present project aims at employing egf as therapeutic agent for mucositis dealing with the challenges of delivery of such macromolecule to the oral mucosa by using self-healing gels to maximize the drug effect.


Eligibility criteria:
inclusion criteria: * eligible patients are those over 18 years of age with who grade 3 or 4 oral mucositis receiving radio- or chemotherapy as treatment for head and neck cancer. exclusion criteria: * patients with hematologic malignancies or those with known allergic reactions to the drug.
pharmacokinetic interaction between hgp0904, hgp0608 and hgp1405

Conditions: Hypertension(HTN)

Summary: the purpose of this study is to investigate the pharmacokinetic interaction and safety between hgp0904, hgp0608 and hgp1405 when administered alone and in combination in healthy male volunteers


Eligibility criteria:
inclusion criteria: * 19\~45 years old * healthy men exclusion criteria: * gastroentestinal disease affecting drug absorption
a study to assess the safety and tolerability of different doses of pf-06444753 and pf-06444752 in subjects with allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to assess the safety and tolerability of different doses of pf-06444753 and pf-06444752 in subjects with allergic rhinitis.


Eligibility criteria:
inclusion criteria: * healthy, males or females of non-child bearing potential, who are between 18 and 55 years, inclusive, * intermittent or persistent allergic rhinitis that is associated with perennial or seasonal allergen reactivity at screening as determined by a positive specific ige level ≥1 ku/l to at least one of the following common allergens: dust mite (dermatophagoides farinae or dermatophagoides pteronyssinus), cat, dog, mold (alternaria), bermuda grass, common ragweed, oak, timothy grass or elm. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease that may compromise their ability to safely participate in the study. * evidence or history of clinically significant pulmonary disease (including allergic and non-allergic asthma, chronic obstructive pulmonary disease \[copd\], cystic fibrosis, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary fibrosis, pulmonary hypertension, or others). * evidence or history of clinically significant autoimmune disease (including rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, or others).

Keywords: vaccines phase 1 allergic rhinitis